DARE Logo

Daré Bioscience, Inc. (DARE) 

NASDAQ
Market Cap
$27.71M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
636 of 960
Rank in Industry
353 of 550

Largest Insider Buys in Sector

DARE Stock Price History Chart

DARE Stock Performance

About Daré Bioscience, Inc.

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; …

Insider Activity of Daré Bioscience, Inc.

Over the last 12 months, insiders at Daré Bioscience, Inc. have bought $0 and sold $0 worth of Daré Bioscience, Inc. stock.

On average, over the past 5 years, insiders at Daré Bioscience, Inc. have bought $0 and sold $0 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 454,545 shares for transaction amount of $500,000 was made by HAWLEY ROGER (director) on 2019‑04‑11.

List of Insider Buy and Sell Transactions, Daré Bioscience, Inc.

2019-04-11Purchasedirector
454,545
2.8482%
$1.10$500,000-22.94%
2018-06-11Purchasedirector
140,000
1.2031%
$1.45$203,378-35.81%
2016-02-22Purchasedirector
1,182
0.0043%
$2.09$2,468-32.54%
2016-02-19Purchasedirector
3,400
0.0125%
$2.08$7,058-27.67%
2016-02-18Purchasedirector
9,000
0.033%
$2.09$18,802-25.96%
2016-02-17Purchasedirector
8,920
0.0329%
$2.12$18,882-17.62%
2016-02-16Purchasedirector
9,000
0.0325%
$2.00$18,028-5.17%
2016-02-12Purchasedirector
8,622
0.0324%
$2.00$17,263+1.03%
2016-02-11Purchasedirector
8,700
0.0324%
$2.03$17,665-1.51%
2016-02-10Purchasedirector
9,000
0.0335%
$2.08$18,679-3.43%
2016-02-09Purchasedirector
9,000
0.0333%
$2.08$18,697-3.17%
2016-02-08Purchasedirector
9,000
0.0344%
$2.15$19,318-2.93%
2016-02-05Purchasedirector
9,000
0.033%
$2.29$20,651-11.79%
2016-02-04Purchasedirector
8,126
0.0294%
$2.31$18,761-13.09%
2016-02-03Purchasedirector
8,036
0.0294%
$2.27$18,262-10.57%
2016-02-02Purchasedirector
8,790
0.0331%
$2.37$20,818-11.30%
2016-02-01Purchasedirector
9,000
0.0329%
$2.37$21,328-13.50%
2016-01-29Purchasedirector
2,400
0.0088%
$2.40$5,772-14.17%
2016-01-28Purchasedirector
9,000
0.034%
$2.45$22,036-12.87%
2016-01-27Purchasedirector
9,000
0.0331%
$2.46$22,132-15.16%

Insider Historical Profitability

<0.0001%
Crane Alan L
4771739
54.8451%
$3.1910
Polaris Venture Management Co. V, L.L.C.10 percent owner
3262437
37.4976%
$3.1910
VENROCK ASSOCIATES V LP10 percent owner
3015017
34.6538%
$3.1910
CVF, LLC10 percent owner
2592577
29.7984%
$3.1920
LILLY ELI & CO10 percent owner
2356227
27.0819%
$3.1910

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.